Objective: To describe the association between postmenopausal estrogen-only therapy use and 93 risk of ovarian carcinoma, specifically with regard to disease histotype and duration and timing 94 of use. 95 96 Methods: We conducted a pooled analysis of 906 women with ovarian carcinoma and 1,220 97 controls; all 2,126 women included reported having had a hysterectomy. Ten population-based 98 case-control studies participating in the Ovarian Cancer Association Consortium (OCAC), an 99 international consortium whose goal is to combine data from many studies with similar methods 100 so reliable assessments of risk factors can be determined, were included. Self-reported 101 questionnaire data from each study were harmonized and conditional logistic regression was 102 used to examine estrogen therapy's histotype-specific and duration and recency of use 103 associations. 104 105 Results: 43.5% of the controls reported previous use of estrogen therapy. Compared to them, 106 current-or-recent estrogen therapy use was associated with an increased risk for the serous 107 (51.4%, OR=1.63, 95% CI 1.27-2.09) and endometrioid (48.6%, OR=2.00, 95% CI 1.17-3.41). 108
In addition, statistically significant trends in risk according to duration of use were seen among 109 current-or-recent postmenopausal estrogen therapy users for both ovarian carcinoma histotypes 110 (ptrend<0.001 for serous and endometrioid). Compared to controls, current-or-recent users for ten 111 years or more had increased risks of serous ovarian carcinoma (36.8%, OR=1.73, 95% CI 1.26-112 Estrogen-only therapy is one of the most commonly used HT types, hence a more 137 complete characterization of the ET-ovarian carcinoma association is warranted. We have 138 undertaken a pooled analysis of data from the Ovarian Cancer Association Consortium (OCAC) 139 to assess ET's histotype-specific, duration and recency of use associations with risk of ovarian 140 carcinoma. 141
Materials and Methods 142
The OCAC is an international multidisciplinary consortium founded in 2005 143 (http://apps.ccge.medschl.cam.ac.uk/consortia/ocac/index.html). Since many groups worldwide 144 are conducting studies to identify risk factors and genetic variation associated with ovarian 145 carcinoma risk, the goal of the OCAC is to provide a forum in which data from many individual 146 studies with similar methods can be combined so reliable assessments of the risks associated 147 with these factors can be determined. Data were sent by each study investigator to the 148 consortium data coordinating center at Duke University, which cleaned and harmonized these 149
data. 150
For the pooled analysis presented here, 10 population-based case-control studies that 151 were individually conducted and contributed data to the OCAC were included, with seven 152 conducted in the United States and three in Europe. Details regarding each study have been 153 published previously, 10-20 but their main characteristics as well as any overlap with the 154 Collaborative Group's pooled analysis are presented in Table 1 . Cases were women with initial 155 diagnoses of primary ovarian carcinoma (women with primary fallopian tube and peritoneal 156 tumors were excluded). Eligible tumor types included serous, mucinous, endometrioid, and clear 157 cell ovarian carcinomas as well as other epithelial tumor types that were not classified as one of 158 these four main ovarian carcinoma histotypes including mixed cell and Brenner tumors; 159 borderline-malignant tumors were excluded. Controls were women with ovaries (a single ovary 160 was acceptable), who had not been diagnosed with ovarian carcinoma at the time of interview. 161
Reference dates for the women in the studies were usually the dates of diagnosis for the cases 162 and the dates of interview for the controls. The data used in this analysis considered events 163 occurring only prior to the reference dates. All studies included in this analysis had approval 164 from ethics committees and written informed consent was obtained from all study participants. 165
There was a total of 8,095 ovarian carcinoma patients and 13,434 controls across the ten 166 OCAC studies. However, only women who reported having had a simple hysterectomy (without 167 bilateral oophorectomy) were included in our analysis since estrogen-only therapy use is very 168 infrequent among women with intact uteri as it is a confirmed risk factor for endometrial 169 cancer, 21,22 leaving us with 1,432 cases and 1,995 controls. Additional exclusions included 170 women who were less than 50 years of age at reference date (n=387), had a prior primary cancer 171 diagnosis (excluding non-melanoma skin cancer) (n=399), or were missing or had unknown HT 172 information (n=141). We also excluded women who had used HT in an estrogen-progestin 173 combined form (n=246) for simplicity of presentation and since its use is likely to skew the 174 primary effect of estrogen-only therapy. Only women classified as non-Hispanic white, Hispanic 175 white, or black were considered, hence our final subject set consisted of 2,126 women who had 176 undergone hysterectomy, with 906 ovarian carcinoma cases and 1,220 controls ( Figure 1 ). 177
Information regarding HT use in all forms as well as potential confounding variables 178 selected a priori, including age, race-ethnicity, education, oral contraceptive (OC) use, parity, 179 endometriosis, tubal ligation, age at menarche, and body mass index (typically one year before 180 the reference date), was reported by means of self-completed questionnaires or in-person or 181 phone interviews; we did not have information on previous salpingectomy or BRCA status at the 182 time of this analysis. The questions used to ascertain HT use and, more specifically, estrogen-183 only therapy use are presented in Appendix 1, available online at http://links.lww.com/xxx. 184
Age at menopause among women who have had a simple hysterectomy cannot be 185 determined since the women are no longer menstruating but may still have functioning ovaries. 186
Hence, in our primary analysis here, we have only considered estrogen-only therapy use after age 187 50 given that 50 is the approximate average age at menopause for women in these populations. 23 188
The majority of estrogen-only therapy use before age 50 is thus likely to be use when the women 189 were still having regular ovulatory cycles. Given that menopause plays a central role in ovarian 190 carcinoma etiology, it is possible that the added estrogen exposure during the period when 191 endogenous levels of estrogen are naturally high (i.e., before menopause) is less important than 192 exposure at older ages, the majority of which will be in the postmenopausal period. 24 Hence, for 193 the analysis presented here, we have defined estrogen-only therapy use as use after age 50, with 194 women who only used estrogen-only therapy before age 50 included in the baseline 'never' users 195 group. We also conducted sensitivity analyses to see if the results were affected if true 'never' 196 users were used as the baseline comparison group and if estrogen-only therapy use was 197 considered regardless of age at use. 198
A common approach to dealing with the problem of an unknown age at menopause for 199 women who had a hysterectomy is to use their age at simple hysterectomy as their age at 200 menopause. Hence, we conducted a sensitivity analysis to assess the association between 201 estrogen-only therapy use and ovarian carcinoma risk using such an approach. We also 202 conducted sensitivity analyses using ages 48 and 52 instead of 50 as the age at menopause. 203
Estrogen-only therapy use was categorized in terms of its recency and its duration of use 204 (in years). Current use was defined as having last used estrogen-only therapy within the past 205
year, recent use as within the last one to four years, and past use as five or more years before the 206 reference date. Because current and recent estrogen-only therapy users showed similar effects, 207 they were combined in the analyses presented here. Duration of estrogen-only therapy use was 208 summed over all episodes of use and the total categorized into the following groups: 'never' 209 (including <1 year), 1 to <5 years, 5 to <10 years, and 10 or more years of use. Women who used 210 estrogen-only therapy for less than one year were included in the baseline 'never' users group as 211 the recall of such short-term use may be greater in cases than controls. All data were cleaned and 212 checked for internal consistency and clarifications were requested from the study investigators 213 when needed. 214
Study, age, race-ethnicity, education, and OC use were included in all statistical models. 215
We conditioned on study, age in five-year groups (50-54, 55-59, 60-64, 65-69, 70-74, 75+; finer 216 stratification after age 75 was not warranted due to small numbers), race-ethnicity (non-Hispanic 217 white, Hispanic white, and black), and education (less than high school, high school, some 218 college, and college graduate or higher) and we adjusted for OC use in categories as ordinal 219 variables ( 'never' (including <1 year), 1 to <2 years, 2 to <5 years, 5 to <10 years, and 10 or 220 more years for OC use). Tubal ligation, endometriosis, parity, body mass index, and age at 221 menarche were also considered, but their inclusion did not change the beta coefficients for the 222 association between ET use and ovarian carcinoma (including overall, serous, or endometrioid) 223 by more than 10% so the results given below are only adjusted for OC use. Overall, cases were 224 missing 1.7% and 1.1% and controls 1.4% and 0.7% for OC use and education, respectively; 225 missing categories were created for these women so their data could be used in the analysis. 226
Conditional logistic regression was used to calculate odds ratios (ORs) and their 95% 227 confidence intervals (CIs) for the association between estrogen-only therapy use and risk of 228 ovarian carcinoma. This was done for all ovarian carcinoma cases combined and for its four 229 main histotypes. Similar analytic approaches were applied when assessing the effects of recency 230 and duration of use. All p-values reported are two-sided. All analyses were performed using SAS 231 9.4. 232
Results 233
Data from 906 women with ovarian carcinoma (567 serous, 113 endometrioid, 49 234 mucinous, 42 clear cell, 135 epithelial but not specified as one of the four main histotypes) and 235 1,220 controls, all of whom had a simple hysterectomy, were included in our analysis. Of these 236 women, 460 cases (50.8%) and 531 controls (43.5%) reported ever having used estrogen-only 237 therapy after age 50. Compared with the women in the control group, wmen who had used 238 estrogen-only therapy after age 50 had a 30% increased risk of ovarian carcinoma as shown in 239 long-term users of estrogen-only therapy for 10 years or more (both current or recent and past 241 users). 242
In addition, the estrogen-only therapy-ovarian carcinoma association appeared to show 243 distinct histotype-specific associations as presented in Table 3 (serous and endometrioid) and 244 Appendix 2, available online at http://links.lww.com/xxx (mucinous and clear cell). Compared 245 with the women in the control group, current or recent estrogen-only therapy use was statistically 246 significantly associated with an increased risk of both serous (51.4%, OR=1.63, 95% CI 1.27-247 2.09) and endometrioid (48.6%, OR=2.00, 95% CI 1.17-3.41) histotypes, but not mucinous 248 (31.3%, OR=0.93, 95% CI 0.43-2.00) and clear cell (39.0%, OR=0.87, 95% CI 0.40-1.88) 249 histotypes, although the confidence limits for the mucinous and clear cell effect estimates were 250 wide due to small numbers of cases. When we looked at high-grade (moderately differentiated, 251 poorly differentiated, undifferentiated) and low-grade (well differentiated) serous ovarian 252 carcinomas separately, we found increased risks for both and hence the results for all serous 253 cases combined are given. 254
Trends in association with duration of estrogen-only therapy use were observed for the 255 serous (ptrend<0.001) and endometrioid (ptrend<0.001) histotypes among current or recent 256 estrogen-only therapy users. Across all histotypes and duration and timing categories, estrogen-257 only therapy appeared to have the strongest association with risk of endometrioid ovarian 258 carcinoma; compared with the women in the control group, current or recent, long-term users of 259 estrogen-only therapy for 10 years or more had over a four-fold increased risk (34.9%, OR=4.03, 260 95% CI 1.91-8.49). Current or recent, long-term users also had nearly a two-fold increased risk 261 of serous ovarian carcinoma (36.8%, OR=1.73, 95% CI 1.26-2.38) when compared with women 262 in the control group. In addition, there appeared to be elevated risks of 1.49, 2.07, and 1.82 for 263 overall, serous, and endometrioid ovarian carcinoma, respectively, when we compared past, 264 long-term ET users to our baseline 'never' user group (Tables 2 and 3) . 265
Because we assumed that all women in our analysis had an age at menopause of 50, we 266 conducted a sensitivity analysis in which each woman's age at simple hysterectomy was used as 267 her age at menopause, with the duration and timing of use variables re-categorized as such. The 268 results by duration, timing of ET use, and histotype slightly attenuated with ORs of 1.46, 1.64, 269 and 3.72 among current-or-recent ET users of 10 years or more for ovarian carcinoma overall 270 and the serous and endometrioid histotypes, respectively (Appendix 3, available online at 271 http://links.lww.com/xxx). Sensitivity analyses that used a true 'never' user baseline group and 272 redefined ET use regardless of age at menopause or with ages 48 and 52 as the age at menopause 273 did not affect the overall findings (data not shown). Most population-based case-control studies and cohort studies have shown that estrogen-277 only therapy use is associated with an increased risk of ovarian carcinoma and considering our 278 findings together with those recently published by the Collaborative Group, 2 it seems clear that 279 estrogen-only therapy is associated with risk for the serous and endometrioid histotypes of the 280 disease. We found greater increased risk for those who used estrogen-only therapy for 10 years 281 or more, including those who last used it more than 5 years in the past, whereas the Collaborative 282 Group 2 did not. This was surprising given that the individual studies that contributed the most 283 statistical information to their analysis (the Million Women Study (MWS) 7 and the Danish Sex we assessed the estrogen-only therapy risk association according to previous history of 295 endometriosis or not, but did not see any heterogeneity in risk (data not shown). 296
Although the exact mechanism by which estrogen-only therapy might affect serous and 297 endometrioid ovarian carcinoma risk remains unknown, estrogens have long been implicated as 298 etiologic factors. 28 Ovarian carcinogenesis may be a result of the direct effects of unopposed 299 estrogen and an estrogen-rich environment, which would potentially be enhanced by estrogen-300 only therapy use. The use of estrogen-only therapy may also directly stimulate the growth of 301 premalignant or early malignant cells with long-term use increasing the risk of transformation or 302 proliferation. 29 In addition, the fallopian tube fimbriae , a proposed cell of origin for high-grade 303 serous carcinoma, have been shown to proliferate at times when estrogenic influences are greater 304 during the menstrual cycle, 30,31 and this increased activity results in greater cell proliferation 305 which may enhance the risk of mutations and malignant transformation. Estradiol has also been 306 shown to increase ovarian carcinoma cell proliferation in vitro 32 and influence the growth of 307 ovarian tumors in a transplanted mouse model. 33 Therefore, while several hypotheses have been 308 put forth to explain ovarian carcinoma etiology, unopposed estrogen appear to play an important 309 role. 310
Limitations of our analysis include the self-reported nature of our data. Because case-311 control studies inquire about previous exposures when subjects are already aware of their disease 312 status, recall bias is possible as cases may be more likely to search for explanations for their 313 disease and assign greater significance to past events than controls. However, studies have 314 shown high agreement between self-reported estrogen use and prescription data. 34 In addition, 315 case patients have not been shown to preferentially report HT use more than controls. 35 We 316 considered estrogen-only therapy use only after age 50 to be relevant in an attempt to mainly 317 consider only use after ovarian function had ceased. Sensitivity analysis showed little effect 318 when changing this to age 48 or 52, the latter which will only include use that is almost all in the 319 postmenopausal period. 320
A potential concern with case-control studies such as those included in our analysis is 321 that some ineligible women (those who had a bilateral oophorectomy) could have been recruited 322 as controls even though they would not be at risk of developing ovarian carcinoma. However, 323 oophorectomy results in a loss of estrogen production, which may make such women more likely 324 to use estrogen-only therapy, thus potentially biasing our findings towards the null. If this type 325 of bias is present, any association between estrogen-only therapy use and risk of ovarian 326 carcinoma would be underestimated. 327
Our analysis offers evidence of an increased risk of ovarian carcinoma with ET use after 328 the age of 50. This is especially true for risk of serous and endometrioid tumors for long 329 durations of use, shedding light on the distinct histotype-specific etiologies. Although ET use has 330 declined since the WHI, a significant number of women continue to use it today. Physicians and 331 patients should be aware of the risk of ovarian carcinoma associated with its long-term use. 332 333 0.95 Note: OR=odds ratio, CI = confidence interval. * Adjusted for oral contraceptive use (never (including <1), 1 to <2, 2 to <5, 5 to <10, 10+ years) and conditioned on age (50-54, 55-59, 60-64, 65-69, 70-74, 75+), education (less than high school, high school, some college, college graduate or higher), race-ethnicity (non-Hispanic white, Hispanic white, black), and study. † Current-or-recent users included those who used estrogen-only therapy within the last five years prior to their reference age. 0.46 p-trend: 0.35 Note: OR=odds ratio, CI=confidence interval * Adjusted for oral contraceptive use (never (including <1), 1 to <2, 2 to <5, 5 to <10, 10+ years) and conditioned on age (50-54, 55-59, 60-64, 65-69, 70-74, 75+), education (less than high school, high school, some college, college graduate or higher), race-ethnicity (non-Hispanic white, Hispanic white, black), and study. † Current or recent users included those who used estrogen-only therapy within the last five years prior to their reference age.
Figure 1. Flowchart of analysis exclusions

